SML0900
ZLN024
≥98% (HPLC)
Synonym(s):
2-[[2-(2-Bromo-4-methylphenoxy)ethyl]thio]-pyrimidine
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C13H13BrN2OS
CAS Number:
Molecular Weight:
325.22
UNSPSC Code:
12352202
NACRES:
NA.77
Product Name
ZLN024, ≥98% (HPLC)
SMILES string
S(CCOc2c(cc(cc2)C)Br)c1ncccn1
InChI
1S/C13H13BrN2OS/c1-10-3-4-12(11(14)9-10)17-7-8-18-13-15-5-2-6-16-13/h2-6,9H,7-8H2,1H3
InChI key
KWJRSHZSULRJHE-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
ZLN024 is an allosteric activator of AMPK hetero-trimers.
ZLN024 is an allosteric activator of AMPK hetero-trimers. The compound ZLN024 protects against dephosphorylation of Thr172, which is critical for activity, and antagonizes AMPK autoinhibition. ZLM024 improves glucose tolerance and lowers total cholesterol levels in db/db mice.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Dam. 1 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tereza Moore et al.
PloS one, 15(10), e0240517-e0240517 (2020-10-15)
Mitochondrial diseases are a clinically heterogenous group of disorders caused by respiratory chain dysfunction and associated with progressive, multi-systemic phenotype. There is no effective treatment or cure, and no FDA-approved drug for treating mitochondrial disease. To identify and characterize potential
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service